Transperineal template-guided biopsy for diagnosis of prostate cancer in patients with at least two prior negative biopsies
Tóm tắt
To evaluate the prostate cancer (PCa) detection rate, PCa location, PCa significance and complications of a standardized 24-core template-guided transperineal biopsy (TPB) approach in patients with at least two negative transrectal biopsies. We prospectively recruited 50 men who had at least two negative transrectal ultrasound-guided extended biopsies in the past 24 months, a prostate-specific antigen (PSA) < 20 ng/mL, a prostate volume < 100 mL, and life expectancy of at least 90 % at 10 years. All patients underwent a standardized 24-core template-guided TPB biopsy. The PCa detection rate, PCa location, PCa significance, and complications were recorded. Median age was 57.5 years and the median PSA level was 7.3 ng/ml. PCa was detected in 24 patients (48 %). The anterior zone was involved in 16 (32 %) PCa. Six PCa (25 %) were insignificant. Biopsy related complications occurred in 2 patients (4 %). A 24-core TPB is a safe procedure with a high PCa detection rate. Few of the detected PCa are clinically insignificant. Men with at least two negative transrectal biopsies may be counseled to undergo TPB.
Từ khóa
Tài liệu tham khảo
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59(1):61–71.
Cormio L, Scattoni V, Lorusso F, Perrone A, Di Fino G, Selvaggio O, et al. Prostate cancer detection rates in different biopsy schemes. Which cores for which patients? World J Urol. 2012. doi:10.1007/s00345-012-0989-8.
Chun FK, Epstein JI, Ficarra V, Freedland SJ, Montironi R, Montorsi F, et al. Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. Eur Urol. 2010;58(6):851–64.
Campos-Fernandes JL, Bastien L, Nicolaiew N, Robert G, Terry S, Vacherot F, et al. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol. 2009;55(3):600–6.
Kawakami S, Okuno T, Yonese J, Igari T, Arai G, Fujii Y, et al. Optimal sampling sites for repeat prostate biopsy: a recursive partitioning analysis of three-dimensional 26-core systematic biopsy. Eur Urol. 2007;51(3):675–83.
Scattoni V, Raber M, Capitanio U, Abdollah F, Roscigno M, Angiolilli D, et al. The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme. Eur Urol. 2011;60(4):834–41.
Zaytoun OM, Moussa AS, Gao T, Fareed K, Jones JS. Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. J Urol. 2011;186(3):850–4.
Bittner N, Merrick GS, Butler WM, Bennett A, Galbreath RW. Incidence and pathologic features of prostate cancer detected on transperineal template-guided mapping biopsy following negative transrectal ultrasound-guided biopsy. J Urol. 2013. doi:10.1016/j.juro.2013.02.021.
Gershman B, Zietman AL, Feldman AS, McDougal WS. Transperineal template-guided prostate biopsy for patients with persistently elevated PSA and multiple prior negative biopsies. Urol Oncol. 2012. doi:10.1016/j.urolonc.2012.01.001.
Mabjeesh NJ, Lidawi G, Chen J, German L, Matzkin H. High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy. BJU Int. 2012;110(7):993–7.
Pal RP, Elmussareh M, Chanawani M, Khan MA. The role of a standardized 36 core template-assisted transperineal prostate biopsy technique in patients with previously negative transrectal ultrasonography-guided prostate biopsies. BJU Int. 2012;109(3):367–71.
Walz J, Gallina A, Saad F, Montorsi F, Perrotte P, Shariat SF, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol. 2007;25(24):3576–81.
Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005;29(9):1228–42.
Epstein JI, Sanderson H, Carter HB, Scharfstein DO. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology. 2005;66(2):356–60.
Oon SF, Watson RW, O’Leary JJ, Fitzpatrick JM. Epstein criteria for insignificant prostate cancer. BJU Int. 2011;108(4):518–25.
Klatte T, Waldert M, de Martino M, Schatzl G, Mannhalter C, Remzi M. Age-specific PCA3 score reference values for diagnosis of prostate cancer. World J Urol. 2012;30(3):405–10.